Heron Therapeutics

Update in progress

HRTX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Heron Therapeutics, Inc. is a commercial‑stage biotech company using Biochronomer, a drug‑delivery technology that sustains therapeutic levels from a single dose. It markets SUSTOL (granisetron) for chemo‑induced nausea and CINVANTI (aprepitant) for PONV and CINV. It is developing ZYNRELEF (bupivacaine/meloxicam) and APONVIE (IV aprepitant). Formerly A.P. Pharma, renamed 2014. Founded 1983, based in Cary, NC.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.10; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive